Evidence map›Paper›PMID 35836088›Full record

ArticleAnnals of nuclear medicine2022

Pretreatment [

Amina Gihbid, Ghofrane Cherkaoui Salhi, Imane El Alami, Hasnaa Belgadir, Nezha Tawfiq, Karima Bendahou, Mohammed El Mzibri, Rachida Cadi, Naima El Benna, Amal Guensi and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of nuclear medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
3.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. From pixels to predictions: the scrying power of molecular imaging.European journal of nuclear medicine and molecular imaging · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Amina GihbidLaboratory of Viral Oncology, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco.
Ghofrane Cherkaoui SalhiNuclear Medicine Department, Ibn Rochd University Hospital, Hassan II University, Casablanca, Morocco.
Imane El AlamiLaboratory of Viral Oncology, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco.
Hasnaa BelgadirDepartment of Radiology, 20 Août 1953 Hospital, University Hospital Center Ibn Rochd, Hassan II University, Casablanca, Morocco.
Nezha TawfiqMohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.
Karima BendahouMohammed VI Center for Cancer Treatment, Ibn Rochd University Hospital, Casablanca, Morocco.
Mohammed El MzibriBiology and Medical Research Unit, National Center of Energy, Sciences and Nuclear Techniques, Rabat, Morocco.
Rachida CadiLaboratory of Pathophysiology, Molecular Genetics and Biotechnology, Faculty of Sciences Ain Chock, Hassan II University, Casablanca, Morocco.
Naima El BennaDepartment of Radiology, 20 Août 1953 Hospital, University Hospital Center Ibn Rochd, Hassan II University, Casablanca, Morocco.
Amal GuensiNuclear Medicine Department, Ibn Rochd University Hospital, Hassan II University, Casablanca, Morocco.
Meriem KhyattiLaboratory of Viral Oncology, Institut Pasteur du Maroc, 1 Place Louis Pasteur, 20360, Casablanca, Morocco. meriem.khyatti@pasteur.ma.
University of Hassan II Casablanca · MAInstitut Pasteur du Maroc · MACentre Hospitalier Universitaire Ibn Rochd · MANational Centre for Nuclear Energy, Science and Technology · MA

Funding

Institut de Recherche sur le Cancer 201932/ AAP2016
6 · The paper itself

Abstract

objectiveThe present study aimed to assess the prognostic interest of metabolic and anatomic parameters derived from 2-deoxy-2-[

methodsIn this study, pre-treatment [

resultsOur results revealed a significant association between pre-treatment nodal-maximum standardized uptake value (N-SUV max) and N categories (p = 0.01), between pre-treatment node-to-tumor SUV ratio (NTR) and both tumor size (p = 0.01) and N categories (p = 0.009), as well as between metabolic tumor volume (MTV) and both tumor size and NPC overall stage (p < 0.000). In multivariate analyses, pre-treatment N-SUV max, NTR and MTV were significant independent predictors of overall survival, distant metastasis-free survival, and progression-free survival (PFS) (p < 0.05). N-SUV max and MTV were also found to be significant independent predictors of loco-regional recurrence-free survival (p < 0.05), whereas HN-MRI detection of skull-base bone invasion was an independent factor associated with worse PFS in NPC (p = 0.03).

conclusionsThe present study highlights N-SUV max, NTR and MTV derived from [

Indexed as

Fluorodeoxyglucose F18Nasopharyngeal NeoplasmsBiomarkersGlucoseHumansMagnetic Resonance ImagingNasopharyngeal CarcinomaPositron-Emission TomographyPositron Emission Tomography Computed TomographyPrognosisRadiopharmaceuticalsRetrospective StudiesBiomarkersFluorodeoxyglucose F18GlucoseRadiopharmaceuticals[18F]FDG PET/CTHN-MRINasopharyngeal carcinomaPrognosis

Identifiers

PMID35836088
OpenAlexW4285387768

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.